<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362176">
  <stage>Registered</stage>
  <submitdate>29/02/2012</submitdate>
  <approvaldate>1/03/2012</approvaldate>
  <actrnumber>ACTRN12612000258853</actrnumber>
  <trial_identification>
    <studytitle>Pilot study of Resveratrol in patients with Glaucoma</studytitle>
    <scientifictitle>An open label clinical pilot study of the effect of resveratrol in patients with Glaucoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Glaucoma</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dose escalation study where patients with glaucoma are given 1 gram Resveratrol (oral capsule) daily for 2 weeks followed by 5 grams of Resveratrol (oral capsule) daily for 2 weeks.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in electroretinogram (ERG) recordings</outcome>
      <timepoint>2 weeks, 4 weeks and 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>N/A</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with ocular hypertension, mild to moderate glaucoma</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Advanced glaucoma
Pregnancy
Severe renal or hepatic impairment
Documented allergy to Resveratrol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patients will be enrolled from the Glaucoma clinics at the Royal Victorian Eye &amp; Ear Hospital. There will be no allocation or concealment procedure.</concealment>
    <sequence>Non-randomised</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Nil</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/07/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Centre for Eye Research Australia</primarysponsorname>
    <primarysponsoraddress>32 Gisborne Street
East Melbourne
VICTORIA
3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Victorian Eye &amp; Ear Hospital</fundingname>
      <fundingaddress>32 Gisborne Street
East Melbourne
VICTORIA
3002</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aims of this study are to determine whether the electroretinogram (ERG), particularly the Phototopic negative response (PhNR) can be improved in patients with glaucoma who take oral supplementation with Resveratrol (RSV) of different doses. 
Participants undertake full-field ERG testing and their recordings of responses are examined to determine whether there is a difference in ERG parameters between glaucoma patients taking different doses of RSV and after a wash-out period after stopping RSV.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Victorian Eye &amp; Ear Human Research and Ethics Commitee</ethicname>
      <ethicaddress>32 Gisborne Street
East Melbourne
VICTORIA
3002</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/04/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Dan Nguyen</name>
      <address>Royal Victorian Eye &amp; Ear Hospital
32 Gisborne Street
East Melbourne
VICTORA 3002</address>
      <phone>+61 3 9929 8666</phone>
      <fax />
      <email>danqbnguyen@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Dan Nguyen</name>
      <address>32 Gisborne Street
East Melbourne
3002
VICTORIA</address>
      <phone>+61 3 9929 8666</phone>
      <fax />
      <email>danqbnguyen@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Dan Nguyen</name>
      <address>Royal Victorian Eye &amp; Ear Hospital
32 Gisborne Street
East Melbourne
VICTORA 3002</address>
      <phone>+61 3 9929 8666</phone>
      <fax />
      <email>danqbnguyen@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>